Physician profile
Patrick Njoku
NPI 1497945026
$979.02
in general payments reported to CMS, 2019-2025
9 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $109 · 2021: $99.18 · 2022: $204 · 2023: $66.84 · 2024: $83.69 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $301.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $327.18 | 2020-2025 | Biktarvy |
| Viiv Healthcare Company | $202.76 | 2019-2025 | Cabenuva |
| Insmed, INC. | $145.33 | 2019-2025 | Arikayce |
| Electromed, INC. | $129.08 | 2024-2025 | Smartvest |
| Paratek Pharmaceuticals, INC. | $86.08 | 2020-2022 | |
| Janssen Products, Lp | $31.49 | 2021 | |
| Smith+Nephew, INC. | $20.35 | 2019 | |
| Pfizer INC. | $20.30 | 2025 | |
| Merck Sharp & Dohme LLC | $16.45 | 2023 | Dificid, Delstrigo, Pifeltro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Njoku listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.